NYSE: CTLTCatalent Inc Stock
$65.71+1.04 (+1.61%)
Updated Mar 31, 2023
CTLT Price
$65.71
Fair Value Price
N/A
Market Cap
$11.83B
52 Week Low
$40.69
52 Week High
$115.34
P/E
28.95x
P/B
2.41x
P/S
1.7x
PEG
1.27x
Dividend Yield
N/A
Revenue
$4.76B
Earnings
$410.00M
Gross Margin
32.7%
Operating Margin
13.62%
Profit Margin
8.6%
Debt to Equity
1.27
Operating Cash Flow
$329M
Beta
1.14
Next Earnings
May 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
CTLT Overview
Catalent, Inc. provides manufactures branded drug products, biologics, gene therapies, and consumer health products. Catalent was formed in 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services segment of Cardinal Health, Inc. Catalent is headquartered in Somerset, NJ.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CTLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTLT ($65.71) is trading above its intrinsic value of $31.48, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CTLT is poor value based on its earnings relative to its share price (28.95x), compared to the US market average (22.13x)
P/E vs Market Valuation
CTLT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CTLT due diligence checks available for Premium users.
Be the first to know about important CTLT news, forecast changes, insider trades & much more!
CTLT News
Valuation
CTLT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
28.95x
Industry
18.12x
Market
22.13x
CTLT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CTLT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
CTLT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.41x
Industry
1.83x
CTLT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CTLT price to earnings growth (PEG)
For valuing profitable companies with growth potential
CTLT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
CTLT's financial health
Profit margin
Revenue
$1.1B
Net Income
$81.0M
Profit Margin
7%
CTLT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CTLT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.1B
Liabilities
$6.2B
Debt to equity
1.27
CTLT's short-term assets ($2.92B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTLT's long-term liabilities ($4.71B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CTLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$214.0M
Investing
-$608.0M
Financing
$523.0M
CTLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CTLT vs Pharmaceutical Stocks
Catalent Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.